Drug Discovery World

APRIL 3, 2023

When used as precision chemotherapies, the small size of these delivery vehicles compared to standard antibody technologies offers the potential for increased tissue penetration for hard-to-reach sites such as the centre of solid tumours. For gene therapies, the current challenge faced by developers is targeted delivery.

Antibody 52

Antibody Gene Therapy Gene In-Vitro 52

Pharmaceutical Technology

FEBRUARY 15, 2023

“At the small scale, manufacturing between 1 ml and 10 ml is typically not problematic , but it’s not straightforward to replicate processes and technologies once you want to produce tens of litres of formulations,” says Dr Crowe, who manages a team that develop novel analytical assays related to LNPs and nanomaterials for drug delivery.

Bioassay 130

Bioassay Development RNA Drugs 130

Roots Analysis

FEBRUARY 13, 2023

The production of such drug products requires skilled labor, stringent manufacturing protocols and specialized expertise. Additionally, they also require appropriate drug delivery systems to efficiently administer the intervention (in a manner that they can avoid degradation by cellular endonucleases).

Manufacturing 52

Manufacturing Drug Delivery Systems Genetic Engineering RNA 52

XTalks

OCTOBER 1, 2020

Xtalks spoke with WeiQi Lin, MD, PhD, executive vice president, research & development, and principal scientist at DURECT Corporation — a company focused on developing drugs and drug delivery methods in therapeutic areas with significant unmet need — about her transition from academia to industry. Key Moments.

Scientist 52

Scientist In-Vitro Research Life Science 52